新药研发中群体药动学/药效学研究的一般考虑

doi:10.12092/j.issn.1009-2501.2019.11.001

摘要/Abstract

摘要：

群体药动学/药效学研究以及基于此之上的量效关系研究已成为新药研发与监管的工具与重要组成部分。将其有机地嵌入新药研发和评审过程中，将能够使研发和评审更为高效，并回答一些传统药动学/药效学无法回答的问题。作为专家共识，本文对群体药动学/药效学研究在新药研发与评审中的应用、试验设计、模型分析方法、分析结果的质量控制与研究报告内容进行了论述。作者们期望本文能为群体药动学/药效学研究在我国新药研发中的应用提供积极有益的参考。

关键词: 新药研发, 定量药理学, 群体药动学, 药效学, 量效关系, 专家共识

Abstract:

Population pharmacokinetic/pharmacodynamic (PopPK/PD) study and so derived exposure-response study are key components in new drug development and regulatory decision making. Integrating such studies into new drug development will facilitate new drug development and regulatory decision-making processes. As an expert consensus, this document provides the areas of applications, clinical trial designs, modeling analysis methods, quality control concerns and study reporting formats of PopPK/PD studies in new drug development/regulatory submissions. The authors expect this document can be a valuable reference to those scientists and regulatory reviewer who wish to adapt PopPK/PD studies into new drug development and drug approval processes in China.

Key words: new drug development, pharmacometrics, population pharmacokinetics, pharmacodynamics, exposure-response, expert consensus

中图分类号:

R969.1

马广立, 许羚, 陈锐, 陈渊成, 赵维, 刘东阳, 焦正, 李健, 季双敏, 李丽, 李良, 王玉珠, 杨进波, 王亚宁, 孙鹤, 胡蓓, 郑青山, 卢炜. 新药研发中群体药动学/药效学研究的一般考虑[J]. 中国临床药理学与治疗学, doi: 10.12092/j.issn.1009-2501.2019.11.001.

MA Guangli, XU Ling, CHEN Rui, CHEN Yuancheng, ZHAO Wei, LIU Dongyang, JIAO Zheng, LI Jian, JI Shuangmin, LI Li, LI Liang, WANG Yuzhu, YANG Jinbo, WANG Yaning, SUN He, HU Pei, ZHENG Qingshan, LU Wei. General considerations of population pharmacokinetic/pharmacodynamic study in new drug development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, doi: 10.12092/j.issn.1009-2501.2019.11.001.

参考文献

［1］刘东阳, 王鲲, 马广立, 等. 新药研发中定量药理学研究的价值及其一般考虑［J］. 中国临床药理学与治疗学, 2018，23(9):961-973.
［2］U.S. Department of Health and Human Services,Food and Drug Administration, Center for Drug Evaluation and Research (CDER),Center for Biologics Evaluation and Research (CBER).Guidance for Industry Population Pharmacokinetics. 1999.
［3］U.S. Department of Health and Human Services,Food and Drug Administration, Center for Drug Evaluation and Research (CDER),Center for Biologics Evaluation and Research (CBER). Population Pharmacokinetics Guicance for Industry［EB/OL］.(2019-07-12). https://www.fda.gov/media/128793/download.
［4］Pharmaceuticals and Medical Devices Agency. Guideline on Population Pharmacokinetic and Pharmacodynamic Analysis ［EB/OL］.(2019-05-15). http://www.pmda.go.jp/files/000230073.pdf
［5］国家药品监督管理局.化学药物临床药代动力学研究技术指导原则［EB/OL］.(2005-03). http://www.cde.org.cn/zdyz.do?method=largePage&id=2070
［6］国家药品监督管理局.儿科人群药代动力学研究技术指导原则［EB/OL］.(2014-07-11). http://www.nmpa.gov.cn/WS04/CL2196/324067.html.
［7］国家药品监督管理局.抗菌药物药代动力学/药效学研究技术指导原则［EB/OL］.(2017-08-14). http://www.nmpa.gov.cn/WS04/CL2138/300379.html
［8］Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data［J］. J Pharmacokinet Biopharm, 1977, 5(5): 445-479.
［9］Aarons L. Population pharmacokinetics: theory and practice［J］. Br J Clin Pharmacol, 1991, 32(6): 669-670.
［10］Sheiner LB,Ludden TM. Population pharmacokinetics/dynamics［J］. Annu Rev Pharmacol Toxicol, 1992, 32: 185-209.
［11］Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development［J］. Clin Pharmacol Ther, 1992, 51(4): 465-473.
［12］Sheiner L,Wakefield J.Population modelling in drug development［J］. Stat Methods Med Res, 1999, 8(3): 183-193.
［13］Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics［J］. Clin Pharmacol Ther, 1979, 26(3): 294-305.
［14］Jones CD, Sun H, Ette EI. Designing cross-sectional population pharmacokinetic studies: Implications for pediatric and animal studies［J］. Clin Res Regul Aff, 2008, 13(3-4):133-165.
［15］Aarons L,Ogungbenro K. Optimal design of pharmacokinetic studies［J］. Basic Clin Pharmacol Toxicol, 2010, 106(3): 250-255.
［16］E7 Studies in Support of Special Populations: Geriatrics (ICH Guidance). August 1994.
［17］Sheiner LB,Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data［J］. J Pharmacokinet Biopharm, 1983, 11(3): 303-319.
［18］Karlsson MO,Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses［J］. J Pharmacokinet Biopharm, 1993, 21(6):735-750.
［19］Sheiner LB,Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data［J］. J Pharmacokinet Biopharm, 1980, 8(6): 553-571.
［20］Beal SL. Ways to fit a PK model with some data below the quantification limit［J］. J Pharmacokinet Pharmacodyn, 2001, 28(5):481-504.
［21］Tukey JW. Exploratory data analysis［M］. Reading, MA: Addison-Wesley, 1971.
［22］Ette EI,Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics［J］. Pharm Res, 1995, 12(12): 1845-1855.
［23］Jonsson EN,Karlsson MO. Automated covariate model building within NONMEM［J］. Pharm Res, 1998, 15(9): p. 1463-1468.
［24］Kowalski KG,Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test［J］. J Pharmacokinet Pharmacodyn, 2001, 28(3):253-275.
［25］Mandema JW, Verotta D,Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects［J］. J Pharmacokinet Biopharm, 1992, 20(5): 511-528.
［26］Ribbing J, Nyberg J, Caster O,et al. The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models［J］. J Pharmacokinet Pharmacodyn, 2007, 34(4): 485-517.
［27］Gastonguay MR. A full model estimation approach for covariate effects:inference based on clinical importance and estimation precision［abstract］［J］.AAPS J, 2004,6.
［28］Karlsson MO. A full model approach based on the covariance matrix of parameters and covariates［C］. PAGE MEETING, 2012.
［29］Byon W, Smith MK, Chan P, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance［J］. CPT Pharmacometrics Syst Pharmacol, 2013, 2: e51.
［30］Efron B. Estimating the error rate of a prediction rule: Improvement on cross-validation［J］. JAm Stat Assoc, 1983, 78(382): 316-331.
［31］Geisse S. The predictive sample reuse method with applications［J］. J Am Stat Assoc, 1975, 70(350): 320-328.
［32］Stone M. Cross-validatory choice and assessment of statistical predictions［J］. 1974, 36(2): 111-133.
［33］Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling［J］. J Clin Pharmacol, 2003, 43(6): 610-623.
［34］焦正. 基础群体药动学和药效学分析［M］. 北京: 科学出版社, 2019.
［35］Savic RM,Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions［J］. AAPS J, 2009, 11(3): 558-569.
［36］Xu XS, Yuan M, Karlsson MO, et al. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact［J］. AAPS J, 2012, 14(4): 927-936.
［37］Karlsson MO,Savic RM. Diagnosing model diagnostics［J］. Clin Pharmacol Ther, 2007, 82(1): 17-20.
［38］Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models［J］. AAPS J, 2011, 13(2): 143-151.
［39］Wang DD,Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation［J］. J Clin Pharmacol, 2012, 52(1): 39-54.
［40］Nguyen TH, Mouksassi MS, Holford N, et al. Model evaluation of continuous data pharmacometric models: Metrics and graphics［J］. CPT Pharmacometrics Syst Pharmacol, 2017, 6(2): 87-109.
［41］Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation［M］. 2 ed. Springer US,2011.
［42］Bonate PL, Strougo A, Desai A, et al. Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective［J］. AAPS J, 2012, 14(4): 749-758.
［43］Dykstra K, Mehrotra N, Torne CW, et al. Reporting guidelines for population pharmacokinetic analyses［J］. J Clin Pharmacol, 2015, 55(8): 875-887.
［44］尹芳, 王玉珠，郑青山. 茚达特罗上市剂量选择的论战：美国FDA定量药理学审评的故事［J］. 中国临床药理学与治疗学, 2018, 23(9): 1031-1039.
［45］Wang Y, Zhu H, Madabushi R, et al. Model-informed drug development: current US regulatory practice and future considerations［J］. Clin Pharmacol Ther, 2019, 105(4): 899-911.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[3]	马广立, 张菁. 定量药理学在疫苗研发中应用的概述与展望[J]. 中国临床药理学与治疗学, 2023, 28(3): 315-322.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[6]	徐俪颖王淑华张高松黄继汉黄小民. 和胃止泻胶囊治疗腹泻患者的临床疗效和模型化评价[J]. 中国临床药理学与治疗学, 2022, 27(1): 47-55.
[7]	刘维, 薛钧升, 于之恒, 王紫愉, 陈镕, 周田彦. 《基于药代动力学方法支持PD-1/PD-L1单抗治疗肿瘤患者的替代剂量方案选择指南》解读[J]. 中国临床药理学与治疗学, 2022, 27(1): 86-94.
[8]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[9]	郝海平. 我国代谢调控与药物靶标发现研究的进展与展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 955-963.
[10]	高丽丽, 陈蕊, 李禄金, 郑青山. 奥贝胆酸在肝损害患者的剂量选择及FDA定量审评的考虑[J]. 中国临床药理学与治疗学, 2021, 26(7): 760-767.
[11]	张宁远, 郑锡军, 许羚, 刘红霞, 郑青山. 阿尔兹海默病的疾病进展模型与研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 687-694.
[12]	章思亮, 胡琳璘, 邵华, 陈西敬. 性别差异对精神药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(3): 324-331.
[13]	焦正, 李新刚, 尚德为, 董婧, 左笑丛, 陈冰, 刘剑敏, 潘雁, 周田彦, 张菁, 刘东阳, 李禄金, 方翼, 马广立, 丁俊杰, 赵维, 陈锐, 相小强, 王玉珠, 高建军, 谢海棠, 胡蓓, 郑青山. 模型引导的精准用药：中国专家共识（2021版）[J]. 中国临床药理学与治疗学, 2021, 26(11): 1215-1228.
[14]	李文超, 白向荣, 李晓玲, 姜德春. 替加环素在治疗感染性疾病中的群体药代动力学/药效学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(11): 1265-1272.
[15]	郭仙忠, 林荣芳, 林玮玮. 基于群体药动学模型的万古霉素个体化给药软件研制及应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 30-39.